Skip to content

Medical emergency? What to do

Experimental once-a-day asthma drug promising

3-RXPublished September 20, 20052 min read

Key points

  • An experimental asthma drug under development by Novartis AG works quickly and lasts for 24 hours in patients with asthma and smoker's lung, data from a study released on Monday showed.
  • "The combination of 24-hour efficacy and a reassuring safety profile suggest that in time, a once-daily dose of indacaterol could become a new standard of care for bronchodilation in asthma and COPD," said Joerg Reinhardt, Novartis's head of development.
  • Indacaterol is the first once-daily version of a beta2-agonist, a class of drugs that includes treatments by GlaxoSmithKline and Novartis, which have to be taken twice a day, but which have raised concerns about their safety.
  • An FDA panel has ruled that Novartis's Foradil, also a beta2-agonist and known as formoterol, should carry a similar warning.

An experimental asthma drug under development by Novartis AG works quickly and lasts for 24 hours in patients with asthma and smoker's lung, data from a study released on Monday showed.

Novartis said its indacaterol drug, formerly known as QAB149, was well-tolerated in patients and worked when administered just once a day, unlike other drugs of its kind which need twice-daily dosing.

"The combination of 24-hour efficacy and a reassuring safety profile suggest that in time, a once-daily dose of indacaterol could become a new standard of care for bronchodilation in asthma and COPD," said Joerg Reinhardt, Novartis's head of development.

Chronic obstructive pulmonary disease (COPD), caused primarily by smoking, is the fourth-leading cause of death in the world, affecting about 4 percent of the U.S., European and Japanese population.

Indacaterol is the first once-daily version of a beta2-agonist, a class of drugs that includes treatments by GlaxoSmithKline and Novartis, which have to be taken twice a day, but which have raised concerns about their safety.

Glaxo's Advair and Serevent, known as salmeterol, carry a "black box" warning on their packaging about one study which showed people taking Serevent had a higher, albeit small, risk of life-threatening asthma attacks and deaths.

An FDA panel has ruled that Novartis's Foradil, also a beta2-agonist and known as formoterol, should carry a similar warning.

These inhaled drugs are known as long-acting beta agonists and patients take them twice daily to relax bronchial muscles and prevent asthma attacks.

Novartis expects to file the drug for approval in 2007, but analysts at Deutsche Bank noted that respiratory market leader Glaxo was also testing a once-daily drug and planned to combine it with steroids - a commonly prescribed asthma treatment.

The firm also presented data, which showed that its Xolair drug for asthma was safe, well-tolerated and able to maintain stable lung function in studies which lasted more than three years.

Xolair, the first biotech treatment for asthma, has been approved by U.S. regulators but is still awaiting approval in the European Union.

About 300 million people worldwide have asthma, around 15 million of whom suffer from severe persistent asthma, meaning they run a high risk of life-threatening attacks.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underAsthma

Keep reading

Asthma

Oral contraceptives linked to asthma risk

Some women who use oral contraceptives may have an increased risk for asthma, according to results of a Scandinavian study. The effect depends on body mass index (BMI), with the rate of asthma increasing as BMI goes…

2 min read

Asthma

Couch potato kids risk developing asthma

Young children who watch TV for more than 2 hours a day run the risk of developing asthma before their 12th birthday, according to a study of more than 3,000 kids whose health and habits were tracked from birth. "In…

2 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.